Tag: amyotrophic lateral sclerosis (ALS) July 1, 2026 Miller honored with Potamkin Prize for dementia researchRecognized for advancing strategies to develop novel therapies for neurodegenerative diseases.National Leaders May 28, 2026 How WashU’s Tim Miller helped pioneer a major breakthrough for ALSSource: St. Louis Magazine May 6, 2026 In a Milestone for A.L.S., a Treatment Helps Some Patients ImproveSource: The New York Times December 22, 2025 New drug may slow progression of ALS in small group of patients: StudySource: ABC News April 25, 2023 Drug for rare form of ALS, based in part on WashU research, approved by FDAWashington University neurologist led international trials of the drug, tofersen.News Release, Video February 2, 2023 Miller receives Rainwater Prize for Brain ResearchHonored for work developing new kind of therapy for neurodegenerative diseases.National Leaders September 21, 2022 Investigational drug for genetic form of ALS improves disease’s molecular signsExtended use of tofersen may help stabilize muscle strength, control.News Release July 8, 2020 Experimental drug shows early promise against inherited form of ALS, trial indicatesPhase 1/phase 2 trial shows evidence for safety, biological activity of tofersen; phase 3 trial underway.News Release January 6, 2020 Miller receives international innovation prizeRecognized for developing experimental treatment for ALS.National Leaders August 15, 2019 Antisense drugs for Huntington’s, ALS and prion diseases could meet the dire need for brain treatmentsSource: Scientific American May 1, 2019 Experimental ALS treatment could be ‘game-changing’ for genetic ALSSource: CNN July 16, 2018 New ALS therapy in clinical trialsDrug extends survival, reverses some neuromuscular damage in animals.News Release Posts navigation 1 2 Next ›
